Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pyrotinib/rivoceranib

Various toxicites: case report

    • 9 Accesses

    This is a preview of subscription content, log in to check access.

    Reference

    1. Huang L-T, et al. Durable Clinical Response to Pyrotinib After Resistance to Prior Anti-HER2 Therapy for HER2-Positive Advanced Gastric Cancer: A Case Report. Frontiers in Oncology 9: 1453, 20 Dec 2019. Available from: URL: http://doi.org/10.3389/fonc.2019.01453

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Pyrotinib/rivoceranib. Reactions Weekly 1790, 199 (2020). https://doi.org/10.1007/s40278-020-74817-9

    Download citation